Mélanie Thill-Tayara
Dechert (Paris)
Lawyer (Partner)
Mélanie Thill-Tayara is a partner in Dechert’s Paris office and co-lead of the firm’s Life Sciences practice. She focuses her practice on antitrust and competition law, and she regularly represents leading companies in merger notifications before the French and European regulators and coordinates multi-jurisdictional filings. She has handled a significant number of cartel and abuse of dominant position cases before EU and French authorities and courts. Prior to joining Dechert in February 2016, she served as a partner for more than 20 years with two other international law firms. Before that, she was an officer at the European Commission, Directorate-General for Competition, where she participated in numerous dawn raid operations and contributed to several decisions. Recognized in “The Legal 500 Hall of Fame” for her continued excellence, Mélanie Thill-Tayara is ranked as one of the top competition and antitrust lawyers in France by Chambers Europe, GCR100, Who’s Who Legal : France and Best Lawyers France 2020.
Distinctions
Auteurs associés
Laure Arnaud
Dechert (Paris)
Laurence Bary
Dechert (Paris)
Ermine Bolot-Massé
Dechert (Paris)
Alec J. Burnside
Dechert (Brussels)
Michael Cowie
Dechert (Washington)
32816 | Conférences
Articles
5506 Bulletin
3783
While pharmaceutical companies are subject to sector-specific regulations, the industry is not exempt from competition law, as exemplified by the numerous investigations that are regularly conducted by competition authorities around the globe and the magnitude of the sanctions that have been levied on pharmaceutical companies in recent years.
105
In three recent judgments issued on 5 October 2020, the General Court of the European Union ("GCEU") partially annulled the European Commission’s ("Commission") decisions of February 2017 which had authorized onsite unannounced inspections ("dawn raid”) to be carried out at the headquarters of (...)
377
Key Takeaways Following several individual initiatives by member state competition authorities to temporarily relax competition rules in specific sectors, the European Competition Network (which includes the European Commission and all member state competition authorities) has issued a more (...)
83
The pharmaceutical sector stands out as being regularly under the scrutiny of competition authorities throughout Europe and has continued to be a key enforcement priority over the past 18 months, with notable developments in pay-for-delay and excessive pricing cases, as well as on market definition and lifecycle management practices.
56
On 14 November 2019, the Paris Court of Appeal (the “Court”) quashed a decision of the French Competition Authority (“FCA”) of 20 September 2018 in which the latter had imposed € 199 000 fine on Sanicorse for having abused its dominant position on the market for infectious clinical waste (“ICW”) (...)
33
More particularly, the Court affirmed the FCA’s conclusion that Janssen infringed competition law by, on the one hand, disparaging competing fentanyl specialties towards health professionals, emphasizing the risks associated with a switch from Durogesic© to a generic version and, on the other (...)
421
The General Court annuls in part the European Commission’s decision finding the existence of restrictive agreements and an abuse of a dominant position on the market for perindopril, a medicine used to treat hypertension and heart failure* On 12 December 2018, the General Court (“Court”) (...)
122
The General Court of the European Union recently held, in Goldman Sachs v. Commission, that purely financial investors such as investment funds may be held jointly and severally liable for competition law violations implemented by their portfolio companies when they can exercise “decisive (...)
206
EU Court Orders New Assessment of Intel’s Rebates The Court of Justice of the European Union (CJEU) has quashed a ruling by the EU’s General Court which had upheld the European Commission’s (EC) 2009 finding of abuse of dominance by Intel Corporation Inc. Intel was fined €1.06 billion, a record at (...)
320
This article has been nominated for the 2015 Antitrust Writing Awards. Click here to learn more about the Antitrust Writing Awards. The new “Hamon Law” introducing French class actions and its effects on competition and distribution law Introduction In order to balance the powers of economic (...)
3712 Revue
565
Les présentes contributions ont été rassemblées à la suite de la 10ème édition de la conférence annuelle “Demain la concurrence” organisée par la Revue Concurrences le 14 juin 2019, au Ministère de l’Économie et des Finances à Paris. Les débats s’organisaient autour de quatre thèmes. Les membres de la (...)
310
La procédure d’engagements présente un intérêt certain pour les entreprises suspectées d’avoir enfreint le droit de la concurrence, qui évitent ainsi une investigation approfondie et une potentielle amende. Du point de vue des autorités de concurrence, elle constitue également un outil efficace (...)
1076
Interview réalisée par Mélanie Thill-Tayara, Associée, Dechert, Paris. Diplômé de l’Institut d’études politiques de Paris et de l’ENA, vous avez occupé plusieurs postes au sein de la DGCCRF, travaillé pour la Représentation permanente de la France auprès de l’Union européenne et, moins classique, avez (...)
1097
Ce dossier réunit 3 contributions sur les développements récents dans le secteur pharmaceutique. Pour Me Thill-Tayara, avocate chez Dechert Paris et auteur de la première contribution, si l’activisme des autorités de concurrence est motivé, au moins en partie, par le besoin de limiter les dépenses des (...)
664
La troisième table-ronde de la conférence “Demain la concurrence” du 21 février 2014 à Paris, était dédiée au “Règlement 1/2003 et Réseau européen de concurrence 10 ans après : Faut-il étendre la cooperation au contrôle des concentrations et à l’advocacy ?”. Les objectifs pour les auteurs de cette table ronde (...)
Livres
Prix
290€00
2020 Competition Case Law Digest - A Synthesis of EU, US and National Leading Cases
The Digest comprises of 41 essays and is structured in two parts : Part I deals with competition rules in general (procedural rules, unilateral practices, mergers...), whereas Part II is (...)
Date
31 janvier 2020
Prix
290€00
